Literatur
- 1
Aszatalos B F. et al .
Value of high-density
lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular
events in the Veterans Affairs HDL Intervention Trial.
Arterioscler Thromb
Vasc Biol.
2005;
25
2185-2191
- 2
Berneis K. et al .
Ezetimibe alone or in combination with
simvastatin increases small dense low-density lipoproteins in healthy
men: a randomized trial.
Europ Heart J.
2010;
31
1633-1639
- 3
Erdmann E.
Zur aktuellen Debatte über die Senkung des LDL-Cholesterins
durch Ezetimib.
Dtsch Med Wochenschr.
2010;
135
1742
- 4
Hiukka A. et
al .
Long-term effects of fenofibrate on VLDL and HDL
subspecies in participants with type 2 diabetes mellitus.
Diabetologie.
2007;
50
2067-2075
- 5
Krumholz H M, Hayward R A.
Shifting views
on lipid lowering therapy.
BMJ.
2010;
341
332-333
- 6
Musunuru K. et al .
Ion mobility analysis of lipoprotein subfractions
identifies three independent axes of cardiovascular risk.
Arterioscler Thromb
Vasc Biol.
2009;
29
1975-1980
- 7
Villines T C. et al .
The ARBITER 6-HALTS Trial (Arterial Biology
for the Investigation of the Treatment Effects of Reducing Cholesterol
6-HDL and LDL Treatment Strategies in Atherosclerosis): final results
and the impact of medication adherence, dose, and treatment duration.
J Am Coll Cardiol.
2010;
55
2821-2726
Prof. Dr. med. Erland Erdmann
Herzzentrum der Universität zu Köln
Klinik
III für Innere Medizin
Universitätsklinik
zu Köln
Kerpener Str. 62
50937 Köln
Phone: 0221/478-32511
Fax: 0221/478-32512
Email: erland.erdmann@uni-koeln.de
